{"name":"Peter A Campochiaro, MD","slug":"peter-a-campochiaro-md","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Intravitreal injection of Ranibizumab .5 dose","genericName":"Intravitreal injection of Ranibizumab .5 dose","slug":"intravitreal-injection-of-ranibizumab-5-dose","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Intravitreal injection of Ranibizumab .5 dose","genericName":"Intravitreal injection of Ranibizumab .5 dose","slug":"intravitreal-injection-of-ranibizumab-5-dose","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxNMENtcHdwbm5uRFlkLWNJX1BraGxlTllhanQxSUhDMEM3emtTWTRzbTFXU0FGYnlnMVVFdDZick1WM1ZLWmwtSzJYdjhoM1lyY1pkdDNiaWxTS1FwcXg4NGNpcExPeWFDa3NCaEwybW1FQWgta2IyV1hqZjBPMzVUd3JMejNkeFZxajU5NTZQYlJwam15ZEZLa2l4NTFUMFB4U1drdDU2QXJQT2phU3I4aVUzbHY1TVJkYVhFT3N5WUJtSjQ0YzVtbm15VjdaLW5U?oc=5","date":"2025-11-21","type":"pipeline","source":"clinicalleader.com","summary":"Ashvattha Therapeutics Shows Real-World Focus With subQ Bilateral Dosing For Ophthalmology Drug - clinicalleader.com","headline":"Ashvattha Therapeutics Shows Real-World Focus With subQ Bilateral Dosing For Ophthalmology Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxOWC1FRVVFMEdmV25CNVkzdmIzT1JmZ09HTXFxSVgyLXdNYUxIY3RNZ2Nrd2tVNmhVVVg4aHZYYWxwR2FTV2FoTTZyVzZFcmQ4QVZETk5QRGRZeS1odGh6Qjk0aFZBR2k0cmI3S1ltY0Jnb2Y2MUo5ZU1YNnRSZ0ZUMDFTeGR6blZXY3QwZlZqNndXSl9ObUwzM0pSZUR4RDlqb05tb1hXYmdZOXY2bTdrbERWY2FIMHBfZkhGT0pLSnZzSnhsTmYxU2FMU2FhcXZ4cGl2bmlwTEdIeG5keGtpWXhlN3pkdU1Ta1gw?oc=5","date":"2019-06-13","type":"pipeline","source":"Johns Hopkins Medicine","summary":"Implanted Drug ‘Reservoir’ Safely Reduces Injections for People with Macular Degeneration - Johns Hopkins Medicine","headline":"Implanted Drug ‘Reservoir’ Safely Reduces Injections for People with Macular Degeneration","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}